From Wikipedia, the free encyclopedia
Jump to: navigation, search
Decoglurant structure.svg
Systematic (IUPAC) name
Legal status
Legal status
  • Development terminated
CAS Number 911115-16-7
ATC code none
PubChem CID 71533696
ChemSpider 32695160
Chemical data
Formula C21H11F6N5
Molar mass 447.336 g/mol

Decoglurant (INN) (code name RG1578, RO4995819) is a negative allosteric modulator of the mGlu2 and mGlu3 receptors which was under development by Roche for the adjunctive treatment of major depressive disorder.[1][2] Decoglurant progressed as far as phase II clinical trials[1][2] but was ultimately discontinued from further development due to disappointing efficacy results.[3][4]

See also[edit]


  1. ^ a b "Roche - Pipeline". 2014. Retrieved 2014-08-01. 
  2. ^ a b "Roche Group Development Pipeline" (PDF). 2014. Retrieved 2014-08-01. 
  3. ^ "Roche - Pipeline" (PDF). 2015. Retrieved 2015-05-14. 
  4. ^ Janna Lawrence (March 2015). "The Secret Life of ketamine". The Pharmaceutical Journal. 

External links[edit]